1. Home
  2. SDST vs ITRM Comparison

SDST vs ITRM Comparison

Compare SDST & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stardust Power Inc.

SDST

Stardust Power Inc.

HOLD

Current Price

$2.78

Market Cap

27.9M

Sector

Finance

ML Signal

HOLD

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

SELL

Current Price

$0.03

Market Cap

24.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SDST
ITRM
Founded
2022
2015
Country
United States
Ireland
Employees
8
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
24.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SDST
ITRM
Price
$2.78
$0.03
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
76.9K
29.3M
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$947.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.03
52 Week High
$7.67
$1.42

Technical Indicators

Market Signals
Indicator
SDST
ITRM
Relative Strength Index (RSI) 46.63 26.10
Support Level $2.12 N/A
Resistance Level $3.00 $0.39
Average True Range (ATR) 0.22 0.02
MACD 0.07 -0.01
Stochastic Oscillator 82.61 3.34

Price Performance

Historical Comparison
SDST
ITRM

About SDST Stardust Power Inc.

Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: